Get the Stockscreener App
15.88
0.87%
-0.14
After Hours:
15.55
-0.33
-2.08%
Lb Pharmaceuticals Inc stock is traded at $15.88, with a volume of 131.04K.
It is down -0.87% in the last 24 hours and up +0.00% over the past month.
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.
See More
Previous Close:
$16.02
Open:
$16.49
24h Volume:
131.04K
Relative Volume:
9.46
Market Cap:
$319.37M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$14.97
$16.49
1-Week Range:
$14.97
$17.50
52-Week Range:
$14.97
$17.50
Lb Pharmaceuticals Inc Stock (LBRX) Company Profile
Compare LBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LBRX
Lb Pharmaceuticals Inc
|
15.88 | 322.00M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.12 | 99.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.99 | 63.46B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.56 | 59.27B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
736.76 | 44.78B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
334.40 | 37.75B | 3.81B | -644.79M | -669.77M | -6.24 |
Lb Pharmaceuticals Inc Stock (LBRX) Latest News
Novo-Backed Drug Developer MapLight Therapeutics Files for IPO - Bloomberg
Neuro drug developer LB Pharma seeks $300M+ valuation in U.S. IPO - MSN
Layoff Tracker: Arsenal, X4 Lay Off Half of Staff to Cut Costs - BioSpace
Hedge Fund and Insider Trading News: Ray Dalio, Bill Ackman, Warren Buffett, Steve Cohen, Mario Gabelli, Balyasny Asset Management, LB Pharmaceuticals Inc (LBRX), Avista Corp (AVA), and More - Insider Monkey
Schizophrenia drug developer LB Pharma jumps in trading debut - MSN
Wednesday 9/17 Insider Buying Report: LBRX, RAPP - Nasdaq
Major Investors Make Bold Moves in LB Pharmaceuticals Stock! - TipRanks
Vida Ventures raises $5.0m in LB Pharmaceuticals (LBRX) By Investing.com - Investing.com Nigeria
LB Pharmaceuticals Launches $285 Million Initial Public Offering - Global Legal Chronicle
Vida Ventures raises $5.0m in LB Pharmaceuticals (LBRX) - Investing.com
Finance Watch: LB Pharmaceuticals Launches Second-Largest Biopharma IPO Of 2025 In The US - insights.citeline.com
Strong demand for LB Pharma in rare NASDAQ IPO: Public Equity Report - biocentury.com
LB Pharmaceuticals tops 2025 biotech IPO list with $285m Nasdaq debut - Yahoo Finance
Mintz Advises on LB Pharmaceuticals’ $285 Million Initial Public Offering - Mintz
Form 424B4 LB PHARMACEUTICALS INC - StreetInsider
Neuro drug maker LB Pharmaceuticals raises $285 million in U.S. IPO - MSN
LB Pharma valued at $382 million as shares jump in New York debut - Reuters
LB Pharmaceuticals Jumps 27% After Raising $285 Million in IPO - Bloomberg.com
LB Pharmaceuticals shares rise nearly 27% giving biotech valuation of about $382 million - TradingView
Cooley-Led LB Pharmaceuticals Raises Upsized $285M IPO - Law360
Bipolar Disorder Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight - GlobeNewswire
LB Pharmaceuticals Opens At $19, IPO Priced At $15 By Investing.com - Investing.com Canada
LB Pharma Pushes the Biotech IPO Window Open, Bagging $285M for Key Schizophrenia Drug Trial - MedCity News
Biopharma breaks its lengthy IPO drought - Axios
LB Pharmaceuticals Prices $285 Million IPO - MarketScreener
LB Pharmaceuticals prices upsized IPO at $15 per share By Investing.com - Investing.com Nigeria
Neuro drug maker LB Pharmaceuticals raises $285 million in U.S. IPO (LBRX:Pending) - Seeking Alpha
LB Pharmaceuticals prices upsized IPO at $15 per share - Investing.com
LB Pharma prices $285M Nasdaq debut to help develop schizophrenia drug - Endpoints News
LB Pharmaceuticals raises $285 million in US IPO - 1470 & 100.3 WMBD
LBRXLB Pharmaceuticals Latest Stock News & Market Updates - Stock Titan
LB Pharma raises $285M in IPO - Axios
LB Pharmaceuticals Announces Pricing of its Upsized Initial Public Offering - The Manila Times
LB Pharmaceuticals raises $285M in first major biotech IPO since February - BioPharma Dive
$285 Million IPO: Biotech LB Pharmaceuticals Prices Upsized Offering at $15 with Strong Institutional Support - Stock Titan
LB Pharmaceuticals Announces Pricing Of Its Upsized Initial Public Offering - TradingView
IPO Opinion | LB Pharmaceuticals (NASDAQ:LBRX) - Seeking Alpha
LB Pharmaceuticals Files for IPO - MarketScreener
LB Pharma targets $250 million raise in bold IPO move - The Pharma Letter
After a long biotech IPO lull, LB Pharma chances its arm - pharmaphorum
LB Pharmaceuticals targets $322M valuation in IPO for schizophrenia drug - Axios
LB Pharmaceuticals Inc. (LBRX): Schizophrenia Biotech Sets Terms, Readies for Same-Week Debut - Smartkarma
LB Pharma seeks $228M in proposed IPO with hopes to be industry’s first since February - Endpoints News
Lb Pharmaceuticals Inc Stock (LBRX) Financials Data
There is no financial data for Lb Pharmaceuticals Inc (LBRX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.43%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):